GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
Led by Founders Fund and Thrive Capital, the round reflects sustained institutional conviction in cellular rejuvenation biology as …
Interim data in osteogenesis imperfecta show safety remains acceptable, but efficacy thresholds for early stopping were not met
Inclusion in major indexes highlights aTyr’s expanding biotech footprint and investor recognition amid advancing therapeutic pipeline.
Analysts predict transformative biotherapies to lead future cancer treatment breakthroughs, with Oncolytics poised for key role.
Big capital flows into companies marrying AI with cancer treatments suggest early-stage clinical research is shifting its centre …
Funding boost fuels hopes for first disease-modifying treatment in a rare genetic disorder
Megafunding rounds and regulatory momentum reshaped the biotech investment landscape, signaling growing confidence in transformative clinical innovation.
A wave of major financings and collaborations on February 25 signals renewed investor confidence in biotech, with giants …
A landmark multi-hundred million dollar collaboration between Takeda and BridGene Biosciences redefines biotech funding trends this week, joined …
Already a subscriber? Log in